GSK vs. SNY: GSK vs. Sanofi Stock Comparison
How do GSK (GSK) and Sanofi (SNY) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
GSK (GSK) and Sanofi (SNY) are both classified in the Pharmaceuticals sub-industry within the broader Pharmaceuticals industry, placing them in the closest GICS peer bucket.
Both GSK (GSK) and Sanofi (SNY) trade as ADRs — their core financials are comparable, but keep FX, depositary-program fees, and dividend withholding in view for each.
| Profile Item | GSK | SNY |
|---|---|---|
| Name | GSK plc ADR | Sanofi ADR |
| Country/Region | United Kingdom | France |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Pharmaceuticals | Pharmaceuticals |
| GICS Sub-Industry | Pharmaceuticals | Pharmaceuticals |
| Market Capitalization | 100.88 billion USD | 112.71 billion USD |
| Currency | USD | USD |
| Exchange | NYSE | Nasdaq |
| Listing Date | March 28, 1980 | July 1, 2002 |
| Security Type | ADR | ADR |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | GSK | SNY |
|---|---|---|
| Total Return (1Y) | 13.73% | 2.73% |
| Total Return (3Y, Annualized) | 18.65% | 6.89% |
| Total Return (5Y, Annualized) | 7.97% | 3.16% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | GSK | SNY |
|---|---|---|
| Volatility (1Y, Annualized) | 26.25% | 23.60% |
| Beta (5Y) | 0.31 | 0.28 |
| Max Drawdown (5Y) | -37.63% | -33.52% |
| Avg. Volume (3M) | 4.05M | 3.29M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | GSK | SNY |
|---|---|---|
| Sharpe Ratio (1Y) | 0.36 | -0.07 |
| Sortino Ratio (1Y) | 0.56 | -0.10 |
Profitability
ROE (TTM)
GSK (GSK) at 28.27% sits in the top ROE quartile, while Sanofi (SNY) at 5.72% is closer to the peer norm — stronger capital efficiency for GSK.
GSK
Pharmaceuticals, Biotechnology & Life Sciences industry group
28.27%
- Max
- 109.18%
- GSK
- 28.27%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
SNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.72%
- Max
- 109.18%
- Q3
- 6.23%
- SNY
- 5.72%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
For every dollar of sales, both GSK (GSK) at 12.97% and Sanofi (SNY) at 8.20% retain more as net profit than most peers, landing in the top net margin quartile of their industries.
GSK
Pharmaceuticals, Biotechnology & Life Sciences industry group
12.97%
- Max
- 18.05%
- GSK
- 12.97%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
SNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
8.20%
- Max
- 18.05%
- SNY
- 8.20%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both GSK (GSK) at 32.14% and Sanofi (SNY) at 30.89% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.
GSK
Pharmaceuticals, Biotechnology & Life Sciences industry group
32.14%
- Max
- 83.12%
- GSK
- 32.14%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
SNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
30.89%
- Max
- 83.12%
- SNY
- 30.89%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | GSK | SNY |
|---|---|---|
| ROE (TTM) | 28.27% | 5.72% |
| ROA (TTM) | 9.24% | 5.31% |
| Net Margin (TTM) | 12.97% | 8.20% |
| Operating Margin (TTM) | 32.14% | 30.89% |
| Gross Margin (TTM) | 73.79% | 73.68% |
Growth
Revenue Growth
Both GSK (GSK) at 4.11% and Sanofi (SNY) at 5.49% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
GSK (GSK) at 123.15% sits in the top EPS growth quartile, while Sanofi (SNY) at 39.43% is closer to the peer norm — faster per-share earnings growth for GSK.
Growth Metrics
| Metric | GSK | SNY |
|---|---|---|
| Revenue Growth (YoY) | 4.11% | 5.49% |
| Revenue Growth (3Y CAGR) | 3.66% | 4.82% |
| EPS Growth (YoY) | 123.15% | 39.43% |
| EPS Growth (3Y CAGR) | -27.63% | 6.02% |
Financial Strength
Current Ratio (MRQ)
Both GSK (GSK) at 0.86 and Sanofi (SNY) at 1.12 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.
GSK
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.86
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- GSK
- 0.86
- Min
- 0.10
SNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.12
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- SNY
- 1.12
- Min
- 0.10
Debt / Equity (MRQ)
Sanofi (SNY) at 0.27 carries an industry-typical debt-to-equity mix, while GSK (GSK) at 1.30 uses more debt funding than most peers.
GSK
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.30
- Max
- 1.42
- GSK
- 1.30
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
SNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.27
- Max
- 1.42
- Q3
- 0.65
- SNY
- 0.27
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | GSK | SNY |
|---|---|---|
| Current Ratio (MRQ) | 0.86 | 1.12 |
| Debt / Equity (MRQ) | 1.30 | 0.27 |
| Net Debt / EBITDA | 1.88 | 0.96 |
Dividends
Dividend Yield (TTM)
Sanofi (SNY) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile GSK (GSK) reports a yield of 1.57%, ranking against industry peers normally.
GSK
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.57%
- GSK
- 1.57%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
SNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- SNY
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Sanofi (SNY) reports payout ratio above 100% at 119.86%, meaning dividends exceeded current-period earnings and sustainability needs extra context. Meanwhile GSK (GSK) reports 63.33%, ranking against industry peers normally.
GSK
Pharmaceuticals, Biotechnology & Life Sciences industry group
63.33%
- GSK
- 63.33%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
SNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
119.86%
- SNY
- 119.86%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | GSK | SNY |
|---|---|---|
| Dividend Yield (TTM) | 1.57% | 0.00% |
| Dividend Payout Ratio (TTM) | 63.33% | 119.86% |
Valuation
P/E Ratio (TTM)
Both GSK (GSK) at 17.54 and Sanofi (SNY) at 23.40 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.
GSK
Pharmaceuticals, Biotechnology & Life Sciences industry group
17.54
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- GSK
- 17.54
- Q1
- 13.30
- Min
- 0.07
SNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
23.40
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- SNY
- 23.40
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
Both GSK (GSK) at 3.01 and Sanofi (SNY) at 2.21 fetch a relatively low price per dollar of sales, landing in the cheaper P/S ratio quartile of their industries.
GSK
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.01
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- GSK
- 3.01
- Min
- 0.01
SNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.21
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- SNY
- 2.21
- Min
- 0.01
P/B Ratio (MRQ)
Sanofi (SNY) at 1.38 sits in the lower P/B ratio quartile against book while GSK (GSK) at 4.02 is valued near its industry’s middle — SNY is cheaper on assets, though weigh it against ROE and asset quality.
GSK
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.02
- Max
- 13.53
- Q3
- 6.54
- GSK
- 4.02
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
SNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.38
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- SNY
- 1.38
- Min
- -5.59
Valuation Metrics
| Metric | GSK | SNY |
|---|---|---|
| P/E Ratio (TTM) | 17.54 | 23.40 |
| P/S Ratio (TTM) | 3.01 | 2.21 |
| P/B Ratio (MRQ) | 4.02 | 1.38 |
| Free Cash Flow Yield (TTM) | 5.28% | 7.17% |